Showing results (21-30 of 643) with videos related to
Sort By:
Pageof 65
CNS & Neurological Disorders Drug Targets|April 10, 2009
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and interventionRawan Tarawneh, David M HoltzmanAdvances in Experimental Medicine and Biology|February 26, 2020
Amyloid-β and Tau at the Crossroads of Alzheimer's DiseaseGilbert Gallardo, David M HoltzmanSeminars in Immunology|March 2, 2022
APOE mediated neuroinflammation and neurodegeneration in Alzheimer's diseaseSamira Parhizkar, David M HoltzmanNeuron|March 7, 2025
The night's watch: Exploring how sleep protects against neurodegenerationSamira Parhizkar, David M HoltzmanJournal of Neurotrauma|June 9, 2012
Administration of COG1410 reduces axonal amyloid precursor protein immunoreactivity and microglial activation after controlled cortical impact in miceYong Jiang, David L BrodyArchives of Neurology|September 15, 2010
New perspectives on amyloid-beta dynamics after acute brain injury: moving between experimental approaches and studies in the human brainSandra Magnoni, David L BrodyJournal of Neurotrauma|May 1, 2023
Sample Size, Replicability, and Pre-Test Likelihoods-Essential, Overlooked, and Critical Components of Statistical Inference: A Journal of Neurotrauma Guide to Statistical Methods and Study DesignVictor Volovici, David L BrodyScience Translational Medicine|November 8, 2023
Current status of amyloid-targeting immunotherapies for Alzheimer's diseaseG Travis Tabor, David M HoltzmanThe Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 19, 2019
Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's DiseaseDong-Oh Seo, David M HoltzmanThe Journal of Clinical Investigation|February 12, 2019
Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1Michael R Strickland, David M HoltzmanPageof 65